Free Trial
→ The Trump Dump is starting; Get out of stocks now? (From Paradigm Press) (Ad) Buy SYRE Stock  Free SYRE Stock Alerts

Spyre Therapeutics (SYRE) Financials

Spyre Therapeutics logo
$15.11 +0.45 (+3.07%)
Closing price 05/2/2025 04:00 PM Eastern
Extended Trading
$14.97 -0.14 (-0.93%)
As of 05/2/2025 04:24 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Compare
Annual Income Statements for Spyre Therapeutics

Annual Income Statements for Spyre Therapeutics

This table shows Spyre Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2014 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Net Income / (Loss) Attributable to Common Shareholders		 -21 -12 -22 -27 -44 -78 -81 -66 -84 -339 -208
Consolidated Net Income / (Loss)		 -10 -11 -22 -27 -44 -78 -81 -66 -84 -339 -208
Net Income / (Loss) Continuing Operations		 -8.90 -11 -22 -27 -44 -78 -81 -66 -84 -339 -208
Total Pre-Tax Income 		-8.90 -11 -22 -27 -44 -78 -81 -66 -84 -339 -208
Total Operating Income		 -8.90 -11 -22 -28 -45 -80 -81 -66 -85 -242 -209
Total Gross Profit		 0.00 6.09 4.63 5.21 3.89 0.00 0.00 19 2.33 0.89 0.00
Total Revenue		 0.00 6.09 4.63 5.21 3.89 0.00 0.00 19 2.33 0.89 0.00
Operating Revenue		 0.00 6.09 4.63 5.21 3.89 0.00 0.00 19 2.33 0.89 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 8.90 17 27 33 49 80 81 84 87 243 209
Selling, General & Admin Expense		 2.07 5.95 8.39 10 13 16 22 27 29 40 46
Research & Development Expense		 6.83 11 18 23 37 65 60 57 59 220 163
Other Operating Expenses / (Income)		 - - - - - - - 0.00 0.00 -16 0.00
Total Other Income / (Expense), net		 0.00 0.02 0.21 0.44 1.12 2.08 0.59 -0.01 0.84 -97 0.60
Interest & Investment Income		 0.00 0.02 0.24 0.48 1.17 2.14 0.59 0.11 0.84 6.15 21
Other Income / (Expense), net		 - -0.00 -0.04 -0.04 -0.06 -0.06 -0.01 -0.12 0.00 -103 -21
Income Tax Expense		 - - - - - 0.00 0.00 0.14 -0.14 -0.03 0.05
Basic Earnings per Share		 ($77.36) ($19.21) ($2.22) ($1.80) ($2.13) ($2.45) ($1.52) $0.00 $0.00 ($1,114.33) ($257.60)
Weighted Average Basic Shares Outstanding		 32.86K 599.79K 9.79M 15.13M 20.82M 31.95M 53.37M 2.63M 0.00 7.34M 47.49M
Diluted Earnings per Share		 ($77.36) ($19.21) ($2.22) ($1.80) ($2.13) ($2.45) ($1.52) $0.00 $0.00 ($1,114.33) ($257.60)
Weighted Average Diluted Shares Outstanding		 32.86K 599.79K 9.79M 15.13M 20.82M 31.95M 53.37M 2.63M 0.00 7.34M 47.49M
Weighted Average Basic & Diluted Shares Outstanding		 532.38K 599.79K 9.79M 15.13M 20.82M 31.95M 53.37M 65.74M 65.40M 36.15M 60.28M

Quarterly Income Statements for Spyre Therapeutics

This table shows Spyre Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024
Net Income / (Loss) Attributable to Common Shareholders		 -18 -19 -18 -217 -40 -63 -44 -39 -69 -56
Consolidated Net Income / (Loss)		 -18 -19 -18 -217 -40 -63 -44 -39 -69 -56
Net Income / (Loss) Continuing Operations		 -18 -19 -18 -217 -40 -63 -44 -39 -69 -56
Total Pre-Tax Income 		-18 -19 -18 -217 -40 -63 -44 -39 -69 -56
Total Operating Income		 -19 -19 -19 -159 -18 -46 -48 -44 -55 -61
Total Operating Expenses		 19 19 19 160 18 46 48 44 55 61
Selling, General & Admin Expense		 6.95 5.08 5.23 12 8.58 14 13 12 11 11
Research & Development Expense		 12 14 14 148 24 34 35 33 45 50
Total Other Income / (Expense), net		 0.31 0.41 0.35 -58 -22 -17 3.95 5.31 -14 4.96
Interest & Investment Income		 0.29 0.41 0.42 0.35 1.25 4.13 4.43 5.92 5.18 5.78
Other Income / (Expense), net		 0.02 0.00 -0.07 -58 -23 -21 -0.48 -0.61 -19 -0.82
Income Tax Expense		 -0.21 0.06 -0.04 0.01 0.00 - 0.03 0.00 0.02 0.00
Basic Earnings per Share		 ($4.84) $0.00 $0.00 $40.14 $0.86 ($8.61) $0.72 $0.59 $1.06 ($1.19)
Weighted Average Basic Shares Outstanding		 3.77M 0.00 3.77M 3.82M 4.29M 7.34M 36.51M 45.32M 50.89M 47.49M
Diluted Earnings per Share		 ($4.84) $0.00 $0.00 $40.14 $0.86 ($8.61) $0.72 $0.59 $1.06 ($1.19)
Weighted Average Diluted Shares Outstanding		 3.77M 0.00 3.77M 3.82M 4.29M 7.34M 36.51M 45.32M 50.89M 47.49M
Basic & Diluted Earnings per Share		 - $0.00 - - - ($8.61) - - - ($1.19)
Weighted Average Basic & Diluted Shares Outstanding		 61.51M 65.40M 65.40M 101.19M 4.05M 36.15M 40.28M 50.79M 51.43M 60.28M

Annual Cash Flow Statements for Spyre Therapeutics

This table details how cash moves in and out of Spyre Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2014 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Net Change in Cash & Equivalents		 -1.98 27 18 -35 9.64 -1.71 71 -75 19 153 -100
Net Cash From Operating Activities		 -7.34 -11 -19 -25 -32 -66 -76 -54 -80 -100 -157
Net Cash From Continuing Operating Activities		 -7.34 -11 -19 -25 -32 -66 -76 -54 -80 -100 -157
Net Income / (Loss) Continuing Operations		 -10 -11 -22 -27 -44 -78 -81 -66 -84 -339 -208
Consolidated Net Income / (Loss)		 -10 -11 -22 -27 -44 -78 -81 -66 -84 -339 -208
Depreciation Expense		 0.02 0.09 0.13 0.25 0.29 0.42 1.00 1.58 1.57 0.74 0.00
Amortization Expense		 - 0.00 0.10 0.08 -0.59 -0.82 0.07 0.97 0.07 -2.10 -11
Non-Cash Adjustments To Reconcile Net Income		 2.97 1.56 1.18 2.50 5.25 5.86 6.59 7.70 7.10 243 67
Changes in Operating Assets and Liabilities, net		 0.03 -1.33 1.45 -0.20 7.20 7.10 -2.54 1.83 -5.07 -2.88 -4.53
Net Cash From Investing Activities		 -0.22 -4.01 -12 -23 -15 -1.74 -7.60 -23 57 -108 -353
Net Cash From Continuing Investing Activities		 -0.22 -4.01 -12 -23 -15 -1.74 -7.60 -23 57 -108 -353
Purchase of Property, Plant & Equipment		 -0.18 -0.21 -0.21 -0.62 -0.42 -1.49 -4.28 -0.57 -0.04 0.00 0.00
Purchase of Investments		 - -3.77 -20 -64 -62 -92 -129 -133 -40 -167 -599
Sale of Property, Plant & Equipment		 - - - - - - - 0.00 0.00 0.48 0.00
Divestitures		 - - - - - - - 0.00 0.00 18 0.00
Sale and/or Maturity of Investments		 - - 8.45 42 47 92 126 111 97 40 246
Net Cash From Financing Activities		 5.58 42 49 12 57 66 155 1.39 43 361 411
Net Cash From Continuing Financing Activities		 5.58 42 49 12 57 66 155 1.39 43 361 411
Issuance of Common Equity		 - 0.02 49 0.83 3.02 66 155 1.90 43 367 413
Other Financing Activities, net		 - - - 11 54 -0.03 -0.02 -0.51 -0.42 -5.80 -1.84
Other Net Changes in Cash		 - - - - - - 0.05 - -0.11 0.03 -0.00

Quarterly Cash Flow Statements for Spyre Therapeutics

This table details how cash moves in and out of Spyre Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024
Net Change in Cash & Equivalents		 1.24 -4.10 0.14 200 -145 97 39 -182 26 18
Net Cash From Operating Activities		 -15 -18 -18 -17 -35 -31 -29 -62 -29 -37
Net Cash From Continuing Operating Activities		 -15 -18 -18 -17 -35 -31 -29 -62 -29 -37
Net Income / (Loss) Continuing Operations		 -18 -19 -18 -217 -40 -63 -44 -39 -69 -56
Consolidated Net Income / (Loss)		 -18 -19 -18 -217 -40 -63 -44 -39 -69 -56
Amortization Expense		 -0.05 -0.05 0.06 0.04 -0.49 -1.71 -2.42 -3.56 -3.00 -2.42
Non-Cash Adjustments To Reconcile Net Income		 1.39 1.36 1.51 194 12 36 14 9.31 32 11
Changes in Operating Assets and Liabilities, net		 1.43 -1.02 -1.17 6.07 -5.92 -1.86 3.47 -29 10 11
Net Cash From Investing Activities		 16 14 18 6.76 -98 -35 -105 -121 43 -171
Net Cash From Continuing Investing Activities		 16 14 18 6.76 -98 -35 -105 -121 43 -171
Purchase of Investments		 -7.25 -4.50 0.00 - -113 -54 -153 -178 -35 -233
Sale and/or Maturity of Investments		 24 19 18 3.25 - 19 48 58 78 63
Net Cash From Financing Activities		 -0.13 -0.01 0.01 210 -13 164 172 0.36 13 226
Net Cash From Continuing Financing Activities		 -0.13 -0.01 0.01 210 -13 164 172 0.36 13 226
Issuance of Common Equity		 -0.07 - 0.02 - 0.11 367 4.39 0.50 13 395
Other Financing Activities, net		 -0.06 -0.01 -0.01 -0.01 - -5.79 -1.43 - -0.08 -0.33

Annual Balance Sheets for Spyre Therapeutics

This table presents Spyre Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Total Assets		 39 67 56 78 83 162 110 71 342 608
Total Current Assets		 38 66 55 77 75 150 99 62 342 608
Cash & Equivalents		 29 48 13 22 19 90 15 35 189 89
Short-Term Investments		 3.77 16 37 52 53 56 78 21 150 514
Prepaid Expenses		 0.91 1.71 1.61 2.16 2.56 3.52 4.95 6.17 2.25 5.39
Plant, Property, & Equipment, net		 0.35 0.60 0.85 1.02 2.39 5.64 4.55 3.22 0.00 0.00
Total Noncurrent Assets		 0.02 0.04 0.23 0.05 6.29 6.19 6.49 5.67 0.33 0.01
Other Noncurrent Operating Assets		 0.02 0.04 0.23 0.05 6.29 6.19 6.49 5.67 0.33 0.01
Total Liabilities & Shareholders' Equity		 39 67 56 78 83 162 110 71 342 608
Total Liabilities		 2.55 4.10 5.74 10 23 22 26 21 73 91
Total Current Liabilities		 2.52 3.97 5.63 10 18 16 20 15 32 54
Accounts Payable		 0.18 0.17 0.39 0.66 3.15 2.25 3.32 0.68 17 1.27
Accrued Expenses		 2.35 3.73 5.22 9.58 15 14 14 13 13 28
Other Current Liabilities		 - - - - 0.35 0.32 0.44 0.63 1.39 25
Total Noncurrent Liabilities		 0.03 0.13 0.11 0.07 4.74 5.34 5.84 6.18 41 37
Other Noncurrent Operating Liabilities		 - - - - 4.71 5.13 4.61 4.00 41 37
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Redeemable Noncontrolling Interest		 58 - - - - - - 0.00 85 0.00
Total Equity & Noncontrolling Interests		 -22 63 50 67 60 140 84 50 184 518
Total Preferred & Common Equity		 -22 63 50 67 60 140 84 50 184 518
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 185 156
Total Common Equity		 -22 63 50 67 60 140 84 50 -0.91 362
Common Stock		 1.37 108 123 184 255 416 426 476 763 1,334
Retained Earnings		 -24 -45 -73 -117 -195 -276 -342 -426 -764 -972
Accumulated Other Comprehensive Income / (Loss)		 -0.00 -0.00 -0.10 -0.03 0.05 0.01 -0.02 -0.05 0.30 0.18

Quarterly Balance Sheets for Spyre Therapeutics

This table presents Spyre Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024
Period end date 9/30/2022 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024
Total Assets		 92 52 244 207 488 436 421
Total Current Assets		 82 44 240 206 487 436 421
Cash & Equivalents		 39 35 235 91 228 45 72
Short-Term Investments		 35 3.24 0.00 113 257 381 343
Prepaid Expenses		 7.87 5.57 2.88 2.19 2.63 9.74 6.85
Plant, Property, & Equipment, net		 3.56 3.42 0.00 0.00 0.00 0.00 0.00
Total Noncurrent Assets		 5.79 4.65 3.64 1.32 0.33 0.33 0.01
Other Noncurrent Operating Assets		 5.79 4.65 3.64 1.32 0.33 0.33 0.01
Total Liabilities & Shareholders' Equity		 92 52 244 207 488 436 421
Total Liabilities		 24 19 254 66 82 62 94
Total Current Liabilities		 18 13 232 45 43 22 58
Accounts Payable		 4.18 2.06 24 22 19 14 20
Accrued Expenses		 12 9.67 28 16 22 5.68 13
Other Current Liabilities		 0.59 0.61 179 7.51 2.59 2.64 25
Total Noncurrent Liabilities		 6.33 6.16 21 21 39 40 36
Other Noncurrent Operating Liabilities		 4.16 3.82 0.00 21 39 40 36
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Redeemable Noncontrolling Interest		 - - 197 387 253 0.00 0.00
Total Equity & Noncontrolling Interests		 68 34 -207 -245 152 374 327
Total Preferred & Common Equity		 68 34 -207 -245 152 374 327
Preferred Stock		 0.00 0.00 0.00 0.00 185 156 156
Total Common Equity		 68 34 -207 -245 -33 219 172
Common Stock		 475 478 454 456 776 1,066 1,086
Retained Earnings		 -407 -444 -661 -701 -808 -847 -916
Accumulated Other Comprehensive Income / (Loss)		 -0.18 -0.01 0.01 -0.13 -0.36 -0.55 1.46

Annual Metrics and Ratios for Spyre Therapeutics

This table displays calculated financial ratios and metrics derived from Spyre Therapeutics' official financial filings.

Metric 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2014 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% -23.94% 12.47% -25.30% -100.00% 0.00% 0.00% -87.57% -61.96% -100.00%
EBITDA Growth		 0.00% -26.35% -93.38% -26.19% -67.26% -76.34% 0.47% 21.38% -31.51% -316.53% 30.50%
EBIT Growth		 0.00% -27.10% -93.89% -26.32% -64.23% -76.62% -1.35% 19.29% -28.90% -306.89% 33.54%
NOPAT Growth		 0.00% -27.08% -93.60% -26.34% -64.27% -76.70% -1.43% 19.43% -29.14% -185.80% 13.92%
Net Income Growth		 0.00% -9.16% -92.10% -25.52% -62.83% -76.45% -3.37% 18.66% -27.38% -304.21% 38.60%
EPS Growth		 0.00% 75.17% 88.44% 18.92% -18.33% -15.02% 37.96% 18.66% -27.38% 0.00% 76.88%
Operating Cash Flow Growth		 0.00% -49.72% -71.55% -30.65% -30.79% -104.06% -15.35% 29.11% -49.20% -24.66% -57.55%
Free Cash Flow Firm Growth		 0.00% 0.00% -9.46% -66.87% -23.77% -108.46% -21.86% 31.34% -46.74% -65.28% -25.99%
Invested Capital Growth		 0.00% 0.00% -113.52% 136.88% -4,806.71% -68.79% 47.39% -47.28% 41.05% -1,207.92% -20.62%
Revenue Q/Q Growth		 0.00% 0.00% -6.81% 4.75% -27.61% 0.00% 0.00% 24.14% -59.88% -15.94% 0.00%
EBITDA Q/Q Growth		 0.00% 0.00% -7.65% -4.21% -24.31% -8.54% -0.47% 4.10% 1.38% -16.95% 1.84%
EBIT Q/Q Growth		 0.00% 0.00% -7.77% -4.05% -23.60% -8.95% -1.03% 3.38% 1.51% -16.22% 2.23%
NOPAT Q/Q Growth		 0.00% 0.00% -7.59% -4.08% -23.59% -8.96% -1.08% 3.43% 1.49% -12.41% -7.94%
Net Income Q/Q Growth		 0.00% 0.00% -7.41% -3.81% -23.42% -9.21% -1.53% 3.33% 1.90% -15.07% 3.20%
EPS Q/Q Growth		 0.00% 0.00% 84.71% -141.00% -13.90% -0.41% -18.75% 3.33% 1.90% -1,525.10% -6,004.27%
Operating Cash Flow Q/Q Growth		 0.00% 0.00% -25.38% -5.24% -4.30% -16.07% -1.12% -4.14% 1.39% -14.82% -4.07%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% -8.88% 0.96% -17.60% -1.71% -5.05% 2.10% -9.67% -19.13%
Invested Capital Q/Q Growth		 0.00% 0.00% -313.76% 220.16% -620.76% -33.50% -68.21% 11.37% 11.68% -14.23% 1.79%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 100.00% 100.00% 100.00% 100.00% 0.00% 0.00% 100.00% 100.00% 100.00% 0.00%
EBITDA Margin		 0.00% -184.49% -469.08% -526.30% -1,178.50% 0.00% 0.00% -337.38% -3,569.94% -39,087.70% 0.00%
Operating Margin		 0.00% -185.95% -473.34% -531.72% -1,169.32% 0.00% 0.00% -350.33% -3,640.23% -27,347.97% 0.00%
EBIT Margin		 0.00% -185.98% -474.11% -532.53% -1,170.78% 0.00% 0.00% -350.98% -3,640.23% -38,934.88% 0.00%
Profit (Net Income) Margin		 0.00% -185.62% -468.84% -523.27% -1,140.64% 0.00% 0.00% -351.14% -3,598.75% -38,238.15% 0.00%
Tax Burden Percent		 116.22% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.21% 99.84% 99.99% 100.02%
Interest Burden Percent		 99.99% 99.81% 98.89% 98.26% 97.43% 97.33% 99.27% 99.83% 99.02% 98.22% 90.70%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% -529.98% -1,186.40% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% -509.60% -1,173.21% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 467.41% 1,142.60% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 0.00% -62.57% -43.80% -48.08% -75.32% -122.74% -80.93% -58.81% -124.87% -212.49% -52.91%
Cash Return on Invested Capital (CROIC)		 0.00% -729.98% 0.00% -13,373.29% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% -29.28% -41.51% -45.02% -68.03% 0.00% 0.00% -48.44% -93.64% -167.05% 0.00%
Return on Assets (ROA)		 0.00% -29.22% -41.05% -44.24% -66.28% 0.00% 0.00% -48.46% -92.58% -164.06% 0.00%
Return on Common Equity (ROCE)		 0.00% 38.49% -18.02% -48.08% -75.32% -122.74% -80.93% -58.81% -124.87% -32.91% -24.29%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 50.86% -34.46% -54.11% -65.77% -130.25% -57.85% -78.39% -166.61% -184.11% -40.17%
Net Operating Profit after Tax (NOPAT)		 -6.23 -7.92 -15 -19 -32 -56 -57 -46 -59 -170 -146
NOPAT Margin		 0.00% -130.16% -331.34% -372.20% -818.52% 0.00% 0.00% -245.23% -2,548.16% -19,143.58% 0.00%
Net Nonoperating Expense Percent (NNEP)		 0.00% -20.38% -13.19% -13.85% -20.10% -30.09% -21.89% -16.60% -32.88% -85.66% -13.16%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - - -117.97% -92.17% -28.20%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 97.73% 181.31% 193.39% 324.90% 0.00% 0.00% 145.79% 1,225.03% 4,508.58% 0.00%
R&D to Revenue		 0.00% 188.22% 392.03% 438.33% 944.42% 0.00% 0.00% 304.55% 2,515.20% 24,795.94% 0.00%
Operating Expenses to Revenue		 0.00% 285.95% 573.34% 631.72% 1,269.32% 0.00% 0.00% 450.33% 3,740.23% 27,447.97% 0.00%
Earnings before Interest and Taxes (EBIT)		 -8.90 -11 -22 -28 -46 -80 -81 -66 -85 -345 -229
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -8.89 -11 -22 -27 -46 -81 -80 -63 -83 -346 -241
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 23.20 44.72 66.54 92.15 67.45 69.77 13.75 0.00 3.31
Price to Tangible Book Value (P/TBV)		 0.00 0.00 23.20 44.72 66.54 92.15 67.45 69.77 13.75 0.00 3.31
Price to Revenue (P/Rev)		 0.00 0.00 315.60 432.50 1,154.04 0.00 0.00 312.54 297.06 98.34 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 14,770.78 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 301.88 422.83 1,134.87 0.00 0.00 307.57 273.14 19.57 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 0.00 -0.92 -0.97 -1.00 -1.06 -1.15 -1.09 -1.07 -1.11 -1.24 -1.20
Leverage Ratio		 0.00 1.07 1.07 1.09 1.14 1.26 1.22 1.21 1.35 1.30 1.21
Compound Leverage Factor		 0.00 1.07 1.06 1.07 1.11 1.23 1.22 1.21 1.34 1.27 1.10
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 68.86% 30.09%
Noncontrolling Interests to Total Capital		 0.00% 161.51% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 31.48% 0.00%
Common Equity to Total Capital		 0.00% -61.51% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% -0.34% 69.91%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 0.00 0.00 213.07 233.02 258.13 138.12 256.69 129.94 8.45 -4.66 5.53
Noncontrolling Interest Sharing Ratio		 0.00% 161.51% 58.86% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 84.51% 54.08%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 0.00 15.17 16.75 9.77 7.49 4.06 9.11 4.91 4.25 10.68 11.26
Quick Ratio		 0.00 13.10 16.02 8.94 7.28 3.92 8.90 4.66 3.83 10.61 11.16
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -11 -12 -20 -25 -51 -63 -43 -63 -104 -131
Operating Cash Flow to CapEx		 -4,052.49% -5,279.81% -8,886.79% -3,976.58% -7,628.67% -4,402.95% -1,770.44% -9,374.52% -210,905.26% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.16 0.09 0.08 0.06 0.00 0.00 0.14 0.03 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 17.49 9.77 7.16 4.15 0.00 0.00 3.68 0.60 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 0.00 2.99 -0.40 0.15 -7.01 -12 -6.23 -9.17 -5.41 -71 -85
Invested Capital Turnover		 0.00 4.07 3.58 -40.82 -1.13 0.00 0.00 -2.43 -0.32 -0.02 0.00
Increase / (Decrease) in Invested Capital		 0.00 2.99 -3.39 0.55 -7.16 -4.82 5.61 -2.94 3.77 -65 -15
Enterprise Value (EV)		 0.00 0.00 1,397 2,201 4,412 5,464 9,285 5,764 636 17 750
Market Capitalization		 0.00 0.00 1,461 2,251 4,487 5,536 9,432 5,857 692 87 1,197
Book Value per Share		 $0.00 ($37.02) $4.69 $3.02 $2.81 $2.07 $2.92 $1.70 $0.82 ($0.23) $7.04
Tangible Book Value per Share		 $0.00 ($37.02) $4.69 $3.02 $2.81 $2.07 $2.92 $1.70 $0.82 ($0.23) $7.04
Total Capital		 0.00 36 63 50 67 60 140 84 50 269 518
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 0.00 -33 -64 -50 -75 -72 -146 -93 -56 -339 -603
Capital Expenditures (CapEx)		 0.18 0.21 0.21 0.62 0.42 1.49 4.28 0.57 0.04 -0.48 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.00 2.62 -1.04 -0.94 -8.08 -16 -13 -14 -8.11 -30 -49
Debt-free Net Working Capital (DFNWC)		 0.00 36 62 49 66 56 133 79 48 310 554
Net Working Capital (NWC)		 0.00 36 62 49 66 56 133 79 48 310 554
Net Nonoperating Expense (NNE)		 4.11 3.37 6.36 7.86 13 22 24 20 24 169 62
Net Nonoperating Obligations (NNO)		 0.00 -33 -63 -50 -74 -72 -146 -93 -56 -339 -603
Total Depreciation and Amortization (D&A)		 0.02 0.09 0.23 0.32 -0.30 -0.40 1.07 2.55 1.64 -1.35 -11
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 43.07% -22.54% -18.00% -207.84% 0.00% 0.00% -76.74% -348.18% -3,355.19% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 587.72% 1,349.59% 948.36% 1,708.64% 0.00% 0.00% 420.23% 2,043.88% 34,937.92% 0.00%
Net Working Capital to Revenue		 0.00% 587.72% 1,349.59% 948.36% 1,708.64% 0.00% 0.00% 420.23% 2,043.88% 34,937.92% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($77.36) $0.00 $0.00 ($1.80) ($2.13) ($2.45) ($1.52) ($1.00) ($0.99) $0.00 ($257.60)
Adjusted Weighted Average Basic Shares Outstanding		 32.86K 599.79K 13.45M 16.72M 28.82M 29.09M 48.02M 49.36M 84.28M 0.00 47.49M
Adjusted Diluted Earnings per Share		 ($77.36) $0.00 $0.00 ($1.80) ($2.13) ($2.45) ($1.52) ($1.00) ($0.99) $0.00 ($257.60)
Adjusted Weighted Average Diluted Shares Outstanding		 32.86K 599.79K 13.45M 16.72M 28.82M 29.09M 48.02M 49.36M 84.28M 0.00 47.49M
Adjusted Basic & Diluted Earnings per Share		 ($77.36) $0.00 $0.00 ($1.80) ($2.13) ($2.45) ($1.52) ($1.00) $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 532.38K 599.79K 13.45M 15.13M 20.82M 31.95M 53.37M 65.74M 65.40M 0.00 60.28M
Normalized Net Operating Profit after Tax (NOPAT)		 -6.23 -7.92 -15 -19 -32 -56 -57 -46 -59 -170 -146
Normalized NOPAT Margin		 0.00% -130.16% -331.34% -372.20% -818.52% 0.00% 0.00% -245.23% -2,548.16% -19,143.58% 0.00%
Pre Tax Income Margin		 0.00% -185.62% -468.84% -523.27% -1,140.64% 0.00% 0.00% -350.39% -3,604.59% -38,241.08% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% -17.95% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics and Ratios for Spyre Therapeutics

This table displays calculated financial ratios and metrics derived from Spyre Therapeutics' official financial filings.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024
Growth Metrics		 - - - - - - - - - -
Revenue Growth		 -87.56% -95.39% -85.46% 10.08% -100.00% 0.00% -100.00% -100.00% 0.00% 0.00%
EBITDA Growth		 6.96% 3.78% 23.05% -887.33% -127.65% -266.64% -174.88% 77.74% -84.48% 6.55%
EBIT Growth		 7.81% 6.34% 22.86% -869.86% -120.78% -251.27% -155.63% 79.41% -79.41% 7.78%
NOPAT Growth		 7.58% 6.26% 23.06% -610.19% 2.23% -139.61% -154.04% 72.28% -202.08% -33.41%
Net Income Growth		 10.21% 7.94% 24.61% -872.45% -119.96% -235.67% -138.07% 82.11% -72.11% 10.90%
EPS Growth		 10.21% 7.94% 24.61% -872.45% 117.77% 0.00% 0.00% -98.53% 23.26% 86.18%
Operating Cash Flow Growth		 11.36% 5.85% 32.86% 19.49% -129.61% -71.09% -61.86% -274.02% 14.96% -19.86%
Free Cash Flow Firm Growth		 -129.55% -51.15% 10.40% 629.98% 347.42% 293.03% 403.77% -286.09% -132.22% -185.34%
Invested Capital Growth		 40.84% 41.05% 4.62% -5,053.74% -911.21% -1,207.92% -1,536.28% 77.20% -40.30% -20.62%
Revenue Q/Q Growth		 -72.16% -3.45% 17.86% 247.47% -100.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 16.38% -2.40% 2.09% -1,077.11% 80.72% -64.93% 26.56% 4.66% -59.76% 16.46%
EBIT Q/Q Growth		 16.45% -2.30% 1.51% -1,051.73% 80.98% -62.75% 28.30% 7.25% -65.77% 16.34%
NOPAT Q/Q Growth		 16.36% -2.17% 1.86% -746.78% 88.49% -150.39% -4.05% 7.59% -25.47% -10.58%
Net Income Q/Q Growth		 18.32% -3.22% 2.13% -1,078.38% 81.52% -57.53% 30.58% 11.45% -77.74% 18.44%
EPS Q/Q Growth		 18.32% -3.22% 2.13% -1,078.38% 101.51% -1,101.16% 107.86% 149.17% 223.26% -212.26%
Operating Cash Flow Q/Q Growth		 27.11% -20.39% 2.79% 5.62% -107.88% 10.29% 8.04% -118.09% 52.74% -26.44%
Free Cash Flow Firm Q/Q Growth		 16.79% 1.01% 22.01% 925.03% -61.15% -22.77% 22.74% -605.41% 93.27% -104.57%
Invested Capital Q/Q Growth		 -39.34% 11.68% 10.73% -4,591.34% 72.66% -14.23% -11.68% 34.64% -68.26% 1.79%
Profitability Metrics		 - - - - - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 100.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 -10,563.79% -11,204.17% -9,311.62% -31,544.19% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 -10,778.74% -11,405.95% -9,497.98% -23,146.22% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 -10,764.94% -11,405.36% -9,534.34% -31,602.33% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 -10,479.31% -11,203.57% -9,304.04% -31,552.47% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 98.87% 100.34% 99.81% 100.00% 100.01% 100.00% 100.07% 100.00% 100.03% 100.00%
Interest Burden Percent		 98.46% 97.90% 97.78% 99.84% 96.98% 93.87% 90.82% 86.77% 93.01% 90.69%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -100.73% -124.87% -163.26% -735.54% -281.41% -212.49% -165.81% -102.09% -91.62% -52.91%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 -566.48% -293.40% -163.80% -221.61% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 -551.45% -288.21% -159.84% -221.26% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -100.73% -124.87% -163.26% 1,222.86% 239.16% -32.91% -0.38% -3.14% 14.42% -24.29%
Return on Equity Simple (ROE_SIMPLE)		 -126.47% 0.00% -231.19% 131.44% 119.98% 0.00% -239.20% -49.68% -65.64% 0.00%
Net Operating Profit after Tax (NOPAT)		 -13 -13 -13 -111 -13 -32 -33 -31 -39 -43
NOPAT Margin		 -7,545.11% -7,984.17% -6,648.59% -16,202.35% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -5.49% -7.27% -10.00% -69.27% -19.67% -15.72% -3.98% -2.47% -9.79% -2.85%
Return On Investment Capital (ROIC_SIMPLE)		 - -26.66% - - - -17.47% - - - -8.28%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 3,995.40% 3,023.21% 2,640.40% 1,753.20% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 6,883.33% 8,482.74% 6,957.58% 21,493.02% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 10,878.74% 11,505.95% 9,597.98% 23,246.22% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -19 -19 -19 -217 -41 -67 -48 -45 -74 -62
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -18 -19 -18 -217 -42 -69 -51 -48 -77 -64
Valuation Ratios		 - - - - - - - - - -
Price to Book Value (P/BV)		 11.91 13.75 14.09 0.00 0.00 0.00 0.00 4.33 8.71 3.31
Price to Tangible Book Value (P/TBV)		 11.91 13.75 14.09 0.00 0.00 0.00 0.00 4.33 8.71 3.31
Price to Revenue (P/Rev)		 138.57 297.06 406.97 599.77 1,176.10 98.34 1,993.03 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 125.88 273.14 373.94 568.79 1,350.21 19.57 1,925.72 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 9.86 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.10 -1.11 -1.10 -4.11 -1.33 -1.24 -1.19 -1.76 -1.32 -1.20
Leverage Ratio		 1.30 1.35 1.42 4.73 1.43 1.30 1.23 1.87 1.34 1.21
Compound Leverage Factor		 1.28 1.32 1.39 4.72 1.38 1.22 1.12 1.62 1.25 1.10
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 68.86% 45.59% 41.62% 47.59% 30.09%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% -1,964.19% 273.18% 31.48% 62.47% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 2,064.19% -173.18% -0.34% -8.05% 58.38% 52.41% 69.91%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 14.12 11.49 2.84 -4.96 6.89 -1.98 8.49 7.29 6.97 6.44
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 266.25% 184.99% 84.51% 99.77% 96.93% 115.74% 54.08%
Liquidity Ratios		 - - - - - - - - - -
Current Ratio		 4.65 4.25 3.51 1.03 4.59 10.68 11.38 19.70 7.32 11.26
Quick Ratio		 4.21 3.83 3.07 1.02 4.54 10.61 11.32 19.26 7.20 11.16
Cash Flow Metrics		 - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -17 -17 -13 111 43 33 41 -206 -14 -28
Operating Cash Flow to CapEx		 -1,506,800.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - -
Asset Turnover		 0.05 0.03 0.02 0.01 0.01 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 1.37 0.60 0.30 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - -
Invested Capital		 -6.12 -5.41 -4.83 -226 -62 -71 -79 -52 -87 -85
Invested Capital Turnover		 -0.71 -0.32 -0.24 -0.01 -0.03 -0.02 -0.02 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 4.23 3.77 0.23 -222 -56 -65 -74 175 -25 -15
Enterprise Value (EV)		 731 636 436 698 1,423 17 1,325 677 1,235 750
Market Capitalization		 804 692 474 737 1,240 87 1,371 947 1,494 1,197
Book Value per Share		 $1.10 $0.82 $0.51 ($3.17) ($2.43) ($0.23) ($0.89) $5.43 $3.38 $7.04
Tangible Book Value per Share		 $1.10 $0.82 $0.51 ($3.17) ($2.43) ($0.23) ($0.89) $5.43 $3.38 $7.04
Total Capital		 68 50 34 -10 142 269 406 374 327 518
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -74 -56 -38 -235 -204 -339 -485 -426 -414 -603
Capital Expenditures (CapEx)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -9.14 -8.11 -6.74 -228 -43 -30 -40 -12 -51 -49
Debt-free Net Working Capital (DFNWC)		 65 48 32 7.65 161 310 444 414 364 554
Net Working Capital (NWC)		 65 48 32 7.65 161 310 444 414 364 554
Net Nonoperating Expense (NNE)		 5.11 5.41 5.26 106 27 31 10 7.93 30 13
Net Nonoperating Obligations (NNO)		 -74 -56 -38 -216 -204 -339 -485 -426 -414 -603
Total Depreciation and Amortization (D&A)		 0.35 0.34 0.44 0.40 -0.49 -1.71 -2.42 -3.56 -3.00 -2.42
Debt-free, Cash-free Net Working Capital to Revenue		 -157.36% -348.18% -578.54% -18,542.83% -4,034.35% -3,355.19% -5,840.99% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 1,111.82% 2,043.88% 2,724.29% 623.13% 15,282.45% 34,937.92% 64,601.02% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 1,111.82% 2,043.88% 2,724.29% 623.13% 15,282.45% 34,937.92% 64,601.02% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.19) $0.00 ($0.20) ($2.27) ($9.34) ($8.61) $0.72 $0.59 $1.06 ($1.19)
Adjusted Weighted Average Basic Shares Outstanding		 94.20M 0.00 94.26M 95.57M 4.29M 7.34M 36.51M 45.32M 50.89M 47.49M
Adjusted Diluted Earnings per Share		 ($0.19) $0.00 ($0.20) ($2.27) ($9.34) ($8.61) $0.72 $0.59 $1.06 ($1.19)
Adjusted Weighted Average Diluted Shares Outstanding		 94.20M 0.00 94.26M 95.57M 4.29M 7.34M 36.51M 45.32M 50.89M 47.49M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 ($8.61) $0.00 $0.00 $0.00 ($1.19)
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 61.51M 65.40M 65.40M 101.19M 4.05M 36.15M 40.28M 50.79M 51.43M 60.28M
Normalized Net Operating Profit after Tax (NOPAT)		 -13 -13 -13 -111 -13 -32 -33 -31 -39 -43
Normalized NOPAT Margin		 -7,545.11% -7,984.17% -6,648.59% -16,202.35% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 -10,599.43% -11,165.48% -9,322.22% -31,551.45% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Frequently Asked Questions About Spyre Therapeutics' Financials

When does Spyre Therapeutics's financial year end?

According to the most recent income statement we have on file, Spyre Therapeutics' fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Spyre Therapeutics' net income changed over the last 10 years?

Spyre Therapeutics' net income appears to be on an upward trend, with a most recent value of -$208.02 million in 2024, rising from -$10.35 million in 2014. The previous period was -$338.79 million in 2023. Find out what analysts predict for Spyre Therapeutics in the coming months.

What is Spyre Therapeutics's operating income?
Spyre Therapeutics's total operating income in 2024 was -$208.57 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $208.57 million
How has Spyre Therapeutics revenue changed over the last 10 years?

Over the last 10 years, Spyre Therapeutics' total revenue changed from $0.00 in 2014 to $0.00 in 2024, a change of 0.0%.

How much debt does Spyre Therapeutics have?

Spyre Therapeutics' total liabilities were at $90.68 million at the end of 2024, a 23.7% increase from 2023, and a 3,456.1% increase since 2015.

How much cash does Spyre Therapeutics have?

In the past 9 years, Spyre Therapeutics' cash and equivalents has ranged from $12.82 million in 2017 to $188.89 million in 2023, and is currently $89.42 million as of their latest financial filing in 2024.

How has Spyre Therapeutics' book value per share changed over the last 10 years?

Over the last 10 years, Spyre Therapeutics' book value per share changed from 0.00 in 2014 to 7.04 in 2024, a change of 703.8%.


Related Companies

This page (NASDAQ:SYRE) was last updated on 5/4/2025 by MarketBeat.com Staff
From Our Partners
Warning: “DOGE Collapse” imminent
Elon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...
Altimetry | Sponsored
Shocking AI play that’s beats Nvidia by a country mile
You’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is...
Timothy Sykes | Sponsored
Why Elon put $51 million into this
Why Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT Scientists
True Market Insiders | Sponsored
Trump to redistribute trillions of dollars
Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...
Porter & Company | Sponsored
Will May start the next "Great Depression?"
You probably haven't heard about this yet... But this could be the biggest wealth building opportunity of t...
Behind the Markets | Sponsored
🥾⛏️👷‍♂️ What I Learned From Numerous Mine Visits...
Twenty years ago, I made a decision that changed my life. Instead of sitting behind a desk analyzing mining...
Golden Portfolio | Sponsored
URGENT: This Altcoin Opportunity Won’t Wait – Act Now
The July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...
Crypto Swap Profits | Sponsored
Trump to solve American wealth loss?
Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...
Paradigm Press | Sponsored